.Attribute Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of people along with HER2+ advanced bosom cancer cells as well as energetic or steady human brain metastases revealed steady intracranial activity and wide spread effectiveness of T-DXd.